Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Partnerships Provide Global Foundation For Alvotech

Network Of Deals Gives Company’s Biosimilar Portfolio Worldwide Reach

Executive Summary

A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.

You may also be interested in...



Humira One Year Out: The Largest LOE Event In US Pharma History

Ahead of the first biosimilar Humira product set to launch in less than a year, In Vivo provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.

Alvotech And Fuji Further Expand Biosimilars Partnership

Alvotech and Fuji Pharma have extended their strategic alliance for the commercialization of Alvotech biosimilars in Japan, adding a further early-stage candidate to the list of products covered by the deal that now encompasses six biosimilars.

Alvotech’s Wessman Sets Out Next Steps On Biosimilars Journey

Alvotech ended 2021 by revealing major plans for a SPAC merger that will provide fresh impetus for the biosimilars specialist with an injection of almost $500m in funding. In the first part of an exclusive two-part interview, founder and chairman Robert Wessman tells Generics Bulletin how the firm plans to move forward following the transaction.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

GB150517

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel